Page 285 | ASweetLife

Peer Mentoring Powerful for Diabetes Behavior Change

Dr. Michele Heisler is an associate professor of internal medicine at the University of Michigan and a research scientist at the Center for Clinical…

The CGM tri-lemma: Abbott, Dexcom, or Minimed?

After a year and a half on Abbott’s Freestyle Navigator Continuous Glucose Monitoring System, I’m back to square one. I loved my Abbott.…

Novo Nordisk’s New Insulin Pen for Children Wins GOOD DESIGN Award

The Chicago Athenaeum Museum of Architecture and Design in cooperation with The European Centre for Architecture, Art, Design and Urban Studies have chosen to award Novo Nordisk a 2010 GOOD DESIGN™ Awardfor the NovoPen Echo, a new insulin pen designed specifically with the needs of children in mind...

Novo Nordisk Intends to Appeal Adverse Ruling in Prandin (repaglinide) Patent Case

Novo Nordisk announced it would appeal the US District Court for the Eastern District of Michigan's ruling regarding Novo Nordisk's US patent covering combination drugs Prandin and PrandiMet. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable...

FDA Rejects Afrezza, Mannkind’s Inhaled Insulin

The FDA's Center for Drug Evaluation and Research has issued a complete response letter to Mannkind corp. regarding the New Drug Application (NDA) for Afrezza (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes...

Generic Version of Bayer’s Type 2 Diabetes Drug Precose Approved by FDA

The FDA has given final approval to Mylan Pharmaceuticals Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg. Acarbose is the generic version of Bayer's Precose tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes...